Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Biogen Inc.

    NASDAQ: BIIB · Real-Time Price · USD
    132.87
    -0.32 (-0.24%)
    At close: Jul 03, 2025, 3:50 PM
    132.50
    -0.28%
    After-hours: Jul 03, 2025, 04:57 PM EDT
    -0.24%
    Bid 132.5
    Market Cap 19.47B
    Revenue (ttm) 9.82B
    Net Income (ttm) 1.48B
    EPS (ttm) 10.12
    PE Ratio (ttm) 13.13
    Forward PE 8.62
    Analyst Hold
    Ask 133.01
    Volume 633,328
    Avg. Volume (20D) 1,634,291
    Open 133.49
    Previous Close 133.19
    Day's Range 132.21 - 134.42
    52-Week Range 110.04 - 238.00
    Beta 0.15

    About BIIB

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol BIIB
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for BIIB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Biogen Inc. is scheduled to release its earnings on Jul 31, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    4 months ago
    -4.28%
    Biogen shares are trading lower after the company ... Unlock content with Pro Subscription
    7 months ago
    -1.28%
    Biogen shares are trading lower after Needham downgraded the stock from Buy to Hold.
    news image

    3 days ago · zacks.com

    Biogen Begins Phase III Felzartamab Study for Third Kidney Disease

    BIIB begins phase III dosing of felzartamab primary membranous nephropathy study, targeting a tough-to-treat condition with no approved therapies.

    news image

    1 week ago · businesswire.com

    Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results

    CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared positive topline results from the Phase 1 study of salanersen (ION306/BII...

    news image

    1 week ago · seekingalpha.com

    Biogen: Investors Are Missing The Bigger Picture

    Biogen is an intriguing stock that occupies one of the leading positions in the central nervous system therapeutic market. On May 1, it released fairly strong financial results for the first quarter o...

    news image

    3 weeks ago · seekingalpha.com

    Biogen Inc. (BIIB) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)

    Biogen Inc. (NASDAQ:BIIB ) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 10:40 AM ET Company Participants Robin C. Kramer - Executive VP & CFO Conference Call Participants Salve...

    news image

    1 month ago · schaeffersresearch.com

    Outside Days Offer Intriguing Options Opportunity

    Last week, I took a closer look at outside days on a candlestick chart of the S&P 500 Index (SPX).

    news image

    1 month ago · seekingalpha.com

    Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet

    President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up t...

    news image

    2 months ago · zacks.com

    BIIB's Q1 Earnings Miss, Revenues Top Mark, 2025 EPS Guidance Cut

    Biogen reports mixed first-quarter 2025 results. It also lowers its EPS guidance for the current year.

    news image

    2 months ago · seekingalpha.com

    Biogen Inc. (BIIB) Q1 2025 Earnings Call Transcript

    Biogen Inc. (NASDAQ:BIIB ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Tim Power - Head, Investor Relations Chris Viehbacher - President & Chief Executive Officer Priy...

    news image

    2 months ago · zacks.com

    Biogen (BIIB) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

    Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street e...

    news image

    2 months ago · zacks.com

    Biogen Inc. (BIIB) Q1 Earnings Lag Estimates

    Biogen Inc. (BIIB) came out with quarterly earnings of $3.02 per share, missing the Zacks Consensus Estimate of $3.26 per share. This compares to earnings of $3.67 per share a year ago.

    Add to Watchlist